X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - DRUGS.COM - Clinical Trials News - 04/Sep 22:09

Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema

RAHWAY, N.J.--(BUSINESS WIRE) September 4, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and EyeBio, a wholly-owned subsidiary of Merck & Co., Inc., Rahway, N.J., USA, today announced the initiation of the...

Articles similaires

Sorry! Image not available at this time

Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug

zacks.com - 05/Sep 15:21

The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.

Sorry! Image not available at this time

Twiggy’s Tenmile to become largest shareholder of Lumos Diagnostics

stockhead.com.au - 05/Sep 03:03

A wholly owned subsidiary of Andrew and Nicola Forest’s private investment vehicle Tattarang is set to become the largest shareholder ...

Sorry! Image not available at this time

Twiggy’s Tenmile to become largest shareholder of Lumos Diagnostics

stockhead.com.au - 05/Sep 03:03

A wholly owned subsidiary of Andrew and Nicola Forest’s private investment vehicle Tattarang is set to become the largest shareholder ...

Sorry! Image not available at this time

Perfetti Van Melle Nigeria Limited Ongoing Job Recruitment – Apply Here!

joblistnigeria.com - 04/Sep 08:00

Perfetti Van Melle Nigeria Limited is a wholly owned subsidiary of Perfetti Van Melle group, one of the worlds largest manufacturers and distributors...

Sorry! Image not available at this time

Labcorp Stock Gains From Its Latest Acquisition of BioReference Health

zacks.com - 17/Sep 16:15

LH completes the acquisition of BioReference Health, a wholly-owned subsidiary of OPKO Health. The acquisition includes BioReference Health's...

Sorry! Image not available at this time

Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

drugs.com - 07/Sep 06:09

BASKING RIDGE, N.J. & RAHWAY, N.J., September 7, 2024 – Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01...

Sorry! Image not available at this time

Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

drugs.com - 07/Sep 06:09

BASKING RIDGE, N.J. & RAHWAY, N.J., September 7, 2024 – Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01...

Sorry! Image not available at this time

Convoy Global Holdings Limited successfully defends another shareholder derivative action in Hong Kong

harneys.com - 09/Sep 18:16

On 21 August 2024, the High Court of Hong Kong, Court of First Instance delivered its decision in the latest proceedings concerning Convoy Global...

Sorry! Image not available at this time

Titan and Hanrine Enter into Joint Venture s Earn-In Agreement

entrepreneur.ca - 06:04

Titan and Hanrine Enter into Joint Venture s Earn-In Agreement Titan Minerals Limited (ASX: TTM) (Titan or the Company) refers to its ASX announcement...

Sorry! Image not available at this time

Titan and Hanrine Enter into Joint Venture s Earn-In Agreement

entrepreneur.ca - 06:04

Titan and Hanrine Enter into Joint Venture s Earn-In Agreement Titan Minerals Limited (ASX: TTM) (Titan or the Company) refers to its ASX announcement...

Les derniers communiqués